Although aripiprazole is one of the most used antipsychotics, knowledge about serum concentrations in children and adolescents is scarce and age-specific therapeutic ranges have not been established yet. Data of a routine therapeutic drug monitoring service were analyzed in order to evaluate the relationship between dose and serum concentration of aripiprazole in children and adolescents. The study also aimed to evaluate whether the therapeutic reference range defined for adults with schizophrenia (100–350 ng/ml) is applicable for minors. Data from 130 patients (aged 7–19 years) treated with aripiprazole for different indications in doses of 2–30 mg/day were evaluated. Patient characteristics, doses, serum concentrations and therapeutic outcome were assessed by standardized measures. A positive mean correlation between body weight-corrected daily dose and aripiprazole concentration was found (r_p = 0.59, p < 0.001) with variation in dose explaining 35% of the variability in serum concentrations. Girls had on average 41% higher dose-corrected concentrations than boys (244.9 versus 173.4 mg/l; p = 0.006). Aripiprazole concentrations did not vary with co-medication (p = 0.22). About 70% of all measured serum concentrations were within the recommended therapeutic range for adults. Using a calculation method in all responding patients with an ICD-10 F2 diagnosis for a rough estimation of a preliminary therapeutic window also demonstrated a similar therapeutic range of aripiprazole in minors (105.9–375.3 ng/ml) than for adults. If confirmed in larger samples and more controlled study designs, these data may contribute to the definition of a therapeutic range of aripiprazole concentrations in children and adolescents.

尽管阿立哌唑是最常用的抗精神病药之一，但关于儿童和青少年血清浓度的知识很少，而且尚未确定针对年龄的治疗范围。分析了常规治疗药物监测服务的数据，以评估儿童和青少年阿立哌唑剂量与血清浓度之间的关系。该研究还旨在评估为成年精神分裂症患者定义的治疗参考范围（100-350 ng/ml）是否适用于未成年人。评估了 130 名接受阿立哌唑治疗的患者（年龄 7-19 岁）以 2-30 mg/天的剂量治疗不同适应症的数据。通过标准化措施评估患者特征、剂量、血清浓度和治疗结果。r _p  = 0.59, p  < 0.001）剂量变化解释了血清浓度变化的 35%。女孩的剂量校正浓度平均比男孩高 41%（244.9 对 173.4 mg/l；p  = 0.006）。阿立哌唑浓度不随联合用药而变化（p = 0.22)。所有测量的血清浓度中约有 70% 在推荐的成人治疗范围内。对所有 ICD-10 F2 诊断有反应的患者使用计算方法粗略估计初步治疗窗口也表明阿立哌唑在未成年人中的治疗范围（105.9-375.3 ng/ml）与成人相似。如果在更大样本和更多对照研究设计中得到证实，这些数据可能有助于确定儿童和青少年阿立哌唑浓度的治疗范围。